Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Prevalence of myopia and its complications has been increasing over the past decades, especially among children and adolescents. It reaches record levels in Asia: nearly 80% of the population in some regions in 2012 where the investigators speak in terms of epidemic.
ATROPINE 0.01% eyedrops one drop per day is today an evolutive myopia treatment, whose results are promising.
The investigators use this eye drops in our clinical practice at hospital of Saint-Etienne since 2017.
Few clinical data have been published so far concerning the French population.
The investigators would like to build a database so that the investigators can publish our results and share our experience.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Children with active myopia treated with ATROPINE eye drops |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| data collection | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| previous refractions | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice | every 6 months up to age 18 years |
| refraction of parents | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice | every 6 months up to age 18 years |
| intra-ocular pression | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice | every 6 months up to age 18 years |
| objective refraction after "fog" | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice | every 6 months up to age 18 years |
| cycloplegia with SKIACOL | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice | every 6 months up to age 18 years |
| slit lamp | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice | every 6 months up to age 18 years |
| dilated eye exam | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice | every 6 months up to age 18 years |
| biometrics |
| Measure | Description | Time Frame |
|---|---|---|
| undesirable events collection | measured the tolerance of ATROPINE 0.01% eyedrops. Number of participants with treatment-related adverse events. | every 6 months up to age 18 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Children with active myopia treated with ATROPINE 0.01% eye drops
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Marie Caroline TRONE | Contact | 04 77 82 94 28 | +33 | m.caroline.trone@chu-st-etienne.fr |
| Marie PEURIERE | Contact | 04 77 82 92 72 | +33 | marie.peuriere@chu-st-etienne.fr |
| Name | Affiliation | Role |
|---|---|---|
| Marie Caroline TRONE | CHU de Saint Etienne | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Saint Etienne | Recruiting | Saint-Etienne | 42055 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009216 | Myopia |
| ID | Term |
|---|---|
| D012030 | Refractive Errors |
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D003625 | Data Collection |
| ID | Term |
|---|---|
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D017531 | Health Care Evaluation Mechanisms |
| D011787 | Quality of Health Care |
Not provided
Not provided
Not provided
Not provided
Not provided
|
effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice
| every 6 months up to age 18 years |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |